Orasis Launches Qlosi Starter Packs to Expand Access and Support Demand for Presbyopia Treatment

Orasis Pharmaceuticals announced the nationwide availability of Starter Packs for Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%. The new offering is designed to broaden patient access to the company's presbyopia treatment option while giving eye care professionals (ECPs) an easy, hands-on way to introduce the therapy to appropriate patients.

The rollout marks the next milestone in Qlosi’s commercial expansion. According to Orasis, since its US launch in April 2025, refill rates of Qlosi have exceeded expectations, signaling strong patient satisfaction and sustained use. No serious adverse events have been reported since launch.

“Orasis remains deeply committed to redefining how people think about presbyopia treatment—moving beyond the limitations of reading glasses,” said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals. “This year alone, our direct-to-consumer campaigns have generated over one million clicks from individuals seeking information about Qlosi. With the introduction of Starter Packs, we’re building on significant momentum, and as we look ahead to 2026, we are positioned to expand our outreach to even more people seeking clearer near vision.”

Each Qlosi Starter Pack contains 10 single-use vials—two daily doses for five days of treatment—along with a patient progress tracker and referral card. Packs are delivered directly to prescribing ECPs for distribution. Eye care professionals can contact their Orasis Account Manager for additional details or request Starter Packs directly at Orasis.MySampleCloset.com.